Breaking News, Collaborations & Alliances

Ology Bio & DOD Ink COVID-19 Pact

CDMO to develop, manufacture monoconal antibody for treatment, prevention of infection with COVID-19 virus for Department of Defense

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

The Department of Defense (DOD) awarded a contract valued at $14 million to Ology Bioservices, a biologics contract development and manufacturing organization (CDMO), to develop and manufacture a monoclonal antibody for treatment and prevention of infection with the COVID-19 virus.   This work is supported by the Office of the Assistant Secretary of Defense for Health Affairs with funding from the Defense Health Agency.   Under this program, Ology Bioservices will work with ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters